ARTICLE | Company News

Amgen, Micromet deal

July 18, 2011 7:00 AM UTC

Amgen partnered with Micromet to develop bispecific T cell engager (BiTE) antibodies against three undisclosed solid tumor targets provided by Amgen. Amgen will have a right to select two of the targets for further development and commercialization. Micromet will be primarily responsible for discovery and preclinical testing, while Amgen will lead clinical development and commercialization. ...